Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross-ethnic comparative study

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 33-40

  Luo, Huai Rong ^a,b,c   Poland, Russell E ^a,b,c   Lin, Keh Ming ^a,b,c   Wan, Yu Jui Yvonne ^a,b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; MEPHENYTOIN;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNOLOGY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HOMOZYGOSITY; HUMAN; HYDROXYLATION; MALE; METABOLISM; NORMAL HUMAN; PHENOTYPE; POPULATION; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HUMANS; LOS ANGELES; MALE; MEXICAN AMERICANS; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33745418092     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.003     Document Type: Article

References (29)

1. Daly A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17 (2003) 27-41
2. Xie H.G., Kim R.B., Stein C.M., Wilkinson G.R., and Wood A.J. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol 48 (1999) 402-408
3. Xie H.G., Stein C.M., Kim R.B., Wilkinson G.R., Flockhart D.A., and Wood A.J. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9 (1999) 539-549
4. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52 (2001) 349-355
5. Yamada S., Onda M., Kato S., Matsuda N., Matsuhisa T., Yamada N., et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 36 (2001) 669-672
6. Kaneko A., Bergqvist Y., Taleo G., Kobayakawa T., Ishizaki T., and Bjorkman A. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 9 (1999) 317-326
7. Wrighton S.A., Stevens J.C., Becker G.W., and VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19. correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 306 (1993) 240-245
8. Goldstein J.A., Faletto M.B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J.L., et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 33 (1994) 1743-1752
9. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269 (1994) 15419-15422
10. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., and Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46 (1994) 594-598
11. Ingelman-Sundberg M, Daly AK, Nebert DW. CYP2C19 allele nomenclature. Available from: URL:http://www.imm.ki.se/CYPalleles/cyp2c19.htm. Accessed Apr 6, 2006.
12. Bramness J.G., Skurtveit S., Fauske L., Grung M., Molven A., Morland J., et al. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?. Pharmacogenetics 13 (2003) 383-388
13. Wang L.S., Zhu B., El-Aty A.M., Zhou G., Li Z., Wu J., et al. The influence of St John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 44 (2004) 577-581
14. Kupfer A., and Preisig R. Pharmacogenetics of mephenytoin. a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26 (1984) 753-759
15. Ferguson R.J., De Morais S.M., Benhamou S., Bouchardy C., Blaisdell J., Ibeanu G., et al. A new genetic defect in human CYP2C19. mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284 (1998) 356-361
16. Xiao Z.S., Goldstein J.A., Xie H.G., Blaisdell J., Wang W., Jiang C.H., et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281 (1997) 604-609
17. Ibeanu G.C., Goldstein J.A., Meyer U., Benhamou S., Bouchardy C., Dayer P., et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286 (1998) 1490-1495
18. Ibeanu G.C., Blaisdell J., Ferguson R.J., Ghanayem B.I., Brosen K., Benhamou S., et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290 (1999) 635-640
19. Endrenyi L., and Patel M. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses. the NTV plot. Br J Clin Pharmacol 32 (1991) 159-166
20. Gonzalez H.M., Romero E.M., Peregrina A.A., de J Chavez T., Escobar-Islas E., Lozano F., et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 43 (2003) 1211-1215
21. Mendoza R., Wan Y.J., Poland R.E., Smith M., Zheng Y., Berman N., et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70 (2001) 552-560
22. Inaba T., Jorge L.F., and Arias T.D. Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 25 (1988) 75-79
23. Hanis C.L., Hewett-Emmett D., Bertin T.K., and Schull W.J. Origins of U.S. Hispanics. Implications for diabetes. Diabetes Care 14 (1991) 618-627
24. Vargas-Alarcon G., Garcia A., Bahena S., Melin-Aldana H., Andrade F., Ibanez-de-Kasep G., et al. HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies. Ann Rheum Dis 53 (1994) 755-758
25. Konishi T., Luo H.R., Calvillo M., Mayo M.S., Lin K.M., and Wan Y.J. ADH1B*1, ADH1C*2, DRD2 (-141C Ins), and 5-HTTLPR are associated with alcoholism in Mexican American men living in Los Angeles. Alcohol Clin Exp Res 28 (2004) 1145-1152
26. Bertilsson L., Dahl M.L., Dalen P., and Al-Shurbaji A. Molecular genetics of CYP2D6. clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53 (2002) 111-122
27. Luo H.R., Israel Y., Tu G.C., Eriksson C.J.P., and Zhang Y.P. Genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Chinese population. gender, age, culture, and genotypes of ALDH2. Biochem Genet 43 (2005) 223-227
28. Munoz S., Vollrath V., Vallejos M.P., Miquel J.F., Covarrubias C., Raddatz A., et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8 (1998) 343-351
29. Mulligan C.J., Robin R.W., Osier M.V., Sambuughin N., Goldfarb L.G., Kittles R.A., et al. Allelic variation at alcohol metabolism genes (ADH1B, ADH1C, ALDH2) and alcohol dependence in an American Indian population. Hum Genet 113 (2003) 325-336